Unternehmensübersicht
Xencor, Inc. operates as a clinical-stage biopharmaceutical entity dedicated to the discovery and development of engineered antibodies designed for therapeutic applications in oncology and autoimmune disorders. The company functions within the healthcare sector, specifically targeting the specialized biotechnology industry where innovation in molecular therapeutics is paramount for addressing complex disease states. Its current operational scale is defined by a market capitalization of $813.51M, an annual revenue generation of $125.58M, and an organizational structure supporting 260 employees. These financial figures indicate that the company maintains a substantial market valuation relative to its current revenue base, a characteristic often observed in biotechnology firms where future pipeline potential and intellectual property assets are priced significantly higher than immediate sales performance.
Finanzielle Gesundheit
The company reported total revenue of $125.58M over the trailing twelve months, yet recorded a net income of $-91,923,000 and an EBITDA of $-166,990,000, highlighting a significant disparity between top-line generation and bottom-line profitability that underscores a heavy cost structure typical of clinical-stage development. This gap between revenue and net income reveals that operational expenses and research and development costs substantially outweigh current sales, resulting in a negative profit margin of -73.2%. The gross margin stands at -90.7%, while the operating margin is -189.9%, both of which indicate that the cost of goods sold and general administrative expenses are currently exceeding total revenue, a pattern expected in pre-commercialization phases but requiring careful monitoring. Free cash flow for the period was $-39,165,124, signaling that the company is burning cash to fund its operations and development pipeline, which limits immediate financial flexibility but is a standard necessity for advancing clinical trials. Regarding leverage, the company holds $547.73M in cash against $187.75M in debt, supported by a debt-to-equity ratio of 29.54, suggesting a balance sheet that is heavily weighted toward cash reserves rather than debt obligations. The current ratio is 6.25, indicating a robust ability to meet short-term obligations with liquid assets, providing a significant buffer against liquidity crises. Finally, the return on equity is -14.1% and the return on assets is -12.1%, metrics that reveal that management has not yet generated positive returns on shareholder capital or total assets, reflecting the high-risk, high-investment nature of the current business stage.
Bewertungsanalyse
The valuation metrics present a complex picture due to the lack of profitability, with a trailing P/E ratio listed as N/A and a forward P/E of -3.72, implying that the market does not value the stock based on current earnings multiples but rather on speculative future potential. The price-to-book ratio is 1.25, indicating that the market values the company at a slight premium of 25% above its book value, suggesting confidence in the underlying asset quality and pipeline potential despite current losses. Alternative valuation measures such as the price-to-sales ratio of 6.48 and an EV/EBITDA of -2.86 suggest that investors are pricing the stock based on revenue generation capabilities and enterprise value adjustments rather than earnings power. The stock has traded between a 52-week high of $18.69 and a 52-week low of $6.92, and without the current specific share price to calculate the exact percentage, the valuation range demonstrates significant volatility typical of small-cap biotechnology stocks. The beta value is 1.00, which indicates that the stock price volatility moves in tandem with the broader market, lacking the typical defensive or highly aggressive characteristics often seen in the healthcare sector.
Growth & Income
The company experienced a revenue growth rate of -46.5% year-over-year, while earnings growth is N/A due to continued negative net income, indicating that the business is currently contracting in terms of top-line revenue rather than expanding. Since the company does not pay dividends, the dividend yield is N/A and the payout ratio is 0.0%, which confirms that the company retains all earnings for reinvestment into research and development rather than distributing income to shareholders. This reinvestment strategy is essential for clinical-stage entities that require continuous funding to advance their antibody candidates through regulatory approval processes. Overall, the growth and income profile is characterized by negative revenue growth and zero dividend distribution, reflecting a capital-intensive growth model focused on long-term product commercialization rather than immediate income generation or revenue expansion.